Emerging small-molecule treatments for multiple sclerosis: focus on B cells

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a significant cause of disability in young adults, characterized by immune-mediated myelin sheath damage.
• Current treatments utilizing B-cell targeted therapies, including antibodies and small molecules, have shown efficacy in slowing disease progression.

Purpose of the Study:

• This review focuses on small-molecule drugs impacting B-cell biology for potential use in multiple sclerosis management.
• It examines MS risk genes from a drug target perspective and discusses existing and emerging small-molecule therapies.

Main Methods:

• Review of existing literature on small-molecule drugs affecting B cells in the context of multiple sclerosis.
• Analysis of MS risk genes as potential drug targets.
• Description of current and investigational small-molecule therapies with B-cell activity.

Main Results:

• Small molecules offer diverse actions on B cells, including cytotoxic, anti-inflammatory, and anti-viral effects.
• Current B-cell therapies can be effective but may lead to side effects and toxicity due to B-cell subset depletion.
• Experimental molecules with B-cell effects are also under consideration.

Conclusions:

• A comprehensive understanding of B-cell biology is crucial for developing new multiple sclerosis drugs with enhanced selectivity, efficacy, and safety.
• Small-molecule drugs, particularly post-patent expiry, offer a sustainable healthcare option for managing MS.